# Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

> **NCT03445858** · EARLY_PHASE1 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 22 (actual)

## Conditions studied

- Childhood Solid Tumor
- Childhood Lymphoma
- Relapsed Cancer
- Refractory Cancer
- Adult Solid Tumor
- Adult Lymphoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Decitabine
- **RADIATION:** Hypofractionated Index Site Radiation

## Key facts

- **NCT ID:** NCT03445858
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-12
- **Primary completion:** 2023-11-07
- **Final completion:** 2023-11-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445858, "Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03445858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*